Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17532026 | 0.91 | — | — | |
| SCHEMBL17355440 | 0.91 | ALOX5AP (0.37) | CTSLCTSSCTSK | |
| SCHEMBL17355474 | 0.91 | AR (0.36) | ARHTR2ASLC6A4CTSLCTSS | |
| SCHEMBL17355589 | 0.90 | CYP11B1 (0.36) | CTSSCTSK | |
| SCHEMBL17355448 | 0.90 | AR (0.31) | ARCTSLCTSSCTSK | |
| SCHEMBL17355420 | 0.89 | CTSL (0.33) | ARCTSLCTSSCTSK | |
| SCHEMBL17377921 | 0.89 | GCGR (0.31) | — | |
| SCHEMBL17355562 | 0.87 | SLC7A5 (0.36) | ARCTSLCTSSCTSKPDE2A | |
| SCHEMBL17377957 | 0.86 | — | — | |
| SCHEMBL17365897 | 0.86 | CTSL (0.34) | CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657229-B2 | Liquid crystal compound having difluoromethyleneoxy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657229-B2 | Liquid crystal compound having difluoromethyleneoxy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2957554-A1 | LIQUID-CRYSTALLINE COMPOUND HAVING DIFLUOROMETHYLENEOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2015-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CPNE4, PIEZO1 | AR 3218/4885HTR2A 2901/4885SLC6A4 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.